Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Response Genetics's Equity-to-Asset or its related term are showing as below:
RGDXQ's Equity-to-Asset is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.59 * Ranked among companies with meaningful Equity-to-Asset only.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Response Genetics Equity-to-Asset Related Terms
Response Genetics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Response Genetics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGDXQ vs PSID, GBSN, ETAH: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Response Genetics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Response Genetics Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Response Genetics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Response Genetics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Response Genetics (RGDXQ) has a Equity-to-Asset of 0.68 as of Dec. 2015. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Response Genetics and its competitors.
Is Response Genetics' Equity-to-Asset too high?
Response Genetics' current Equity-to-Asset is 0.68. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Response Genetics' value of 0.68 is 15.3% above this industry median.
How does Response Genetics' Equity-to-Asset compare to PSID and GBSN?
Response Genetics' Equity-to-Asset of 0.68 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Equity-to-Asset is 0.59. Response Genetics' value of 0.68 is 15.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Response Genetics's current Equity-to-Asset of 0.68 is 15.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Response Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Response Genetics's current Equity-to-Asset is 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Equity-to-Asset of 0.68. The current Equity-to-Asset is 0.68 and 15.3% above the Medical Diagnostics & Research industry median of 0.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Equity-to-Asset is 0.68 as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGDXQ has been successfully added to your 
